Duration of eptifibatide infusion after percutaneous coronary intervention and outcomes among high-risk patients with non-ST-segment elevation acute coronary syndrome: insights from EARLY ACS

摘要

Background and Objectives: Eptifibatide is indicated during percutaneous coronary intervention (PCI) with continuation for 18-24 hours post procedure but is associated with bleeding. We examined the efficacy and safety of shorter post-PCI eptifibatide infusions in high-risk non-ST-segment elevation acute coronary syndrome (NSTE ACS) patients. Methods: EARLY ACS patients treated with PCI and eptifibatide were grouped by post-procedure infusion duration: <10, 10-13, 13-17, and 17-25 (per protocol) hours. Adjusted estimated event rates for 96-hour death/myocardial infarction (Ml)/recurrent ischaemia requiring urgent revascularization (RIUR), 30-day death/Ml, post-PCI packed red blood cell (PRBC) transfusion, and GUSTO (Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries) moderate/severe bleeding were obtained using inverse-propensity weighting to account for informative censoring of infusions. Results: Among 3271 eptifibatide-treated PCI patients, there were 66 96-hour death/MI/RlUR events, 94 30-day death/ Ml events, 127 PRBC transfusions, and 115 GUSTO moderate/severe bleeds. Compared with per protocol, patients receiving post-PCI infusions < 10 hours had similar adjusted estimated rates of 96-hour death/MI/RlUR (absolute difference 0.021 higher; 0.040 vs. 0.019, 95% Cl -0.023 to 0.064; p=035) and 30-day death/Ml (0.020 higher; 0.046 vs. 0.026, 95% Cl -0.021 to 0.062; p=0.34). There were also no differences in ischaemic outcomes between infusions of 10-17 hours and per-protocol infusions. Adjusted estimated rates of PRBC transfusion were higher for the < 10-hour infusion group compared with per protocol (0.048 higher; 0.079 vs. 0.03, 95% Cl 0.005 to 0.09, p=0.03) but were similar for other groups. Adjusted GUSTO moderate/severe bleeding rates were similar to per-protocol rates for all groups. Conclusions: In high-risk NSTE ACS patients, post-PCI eptifibatide infusions